Recombinant human erythropoietin pretreatment attenuates acute renal tubular injury against ischemia-reperfusion by restoring transient receptor potential channel-6 expression and function in collecting ducts

Critical Care Medicine

Volumn 42, Issue 10, 2014, Pages e663-e672

  Shen, Sai'E ^a   Jin, Yi ^b   Li, Weiyan ^b   Liu, Xiaoming ^b   Zhang, Tingting ^c   Xia, Weiliang ^c   Wang, Yingwei ^a   Ma, Ke ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b JINLING HOSPITAL   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Aquaporin 2; Ischemia reperfusion injury; Na,K ATPase; Recombinant human erythropoietin; Transient receptor potential channel 6

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AQUAPORIN 2; CYSTATIN C; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; RECOMBINANT ERYTHROPOIETIN; SODIUM; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; ACUTE PHASE PROTEIN; EPO PROTEIN, HUMAN; ERYTHROPOIETIN; LIPOCALIN; NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN PROTEIN, RAT; ONCOPROTEIN; RECOMBINANT PROTEIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL C; TRPC6 PROTEIN, RAT;

ACUTE KIDNEY TUBULE NECROSIS; ACUTE RENAL TUBULAR INJURY; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; KIDNEY CONCENTRATING CAPACITY; KIDNEY FUNCTION; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REPERFUSION; REPERFUSION INJURY; SODIUM URINE LEVEL; URINALYSIS; URINARY EXCRETION; URINE OSMOLALITY; URINE VOLUME; ACUTE KIDNEY INJURY; ANIMAL; BLOOD; CHEMISTRY; HUMAN; KIDNEY COLLECTING TUBULE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; ANIMALS; AQUAPORIN 2; CYSTATIN C; ERYTHROPOIETIN; HUMANS; KIDNEY TUBULES, COLLECTING; LIPOCALINS; MALE; PROTO-ONCOGENE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; REPERFUSION INJURY; SODIUM-POTASSIUM-EXCHANGING ATPASE; TRPC CATION CHANNELS;

EID: 84914101725     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000542     Document Type: Article

References (41)

1. Thakar CV: Perioperative acute kidney injury. Adv Chronic Kidney Dis 2013; 20:67-75
2. Sear JW: Kidney dysfunction in the postoperative period. Br J Anaesth 2005; 95:20-32
3. Nielsen S, Frøkiaer J, Marples D, et al: Aquaporins in the kidney: From molecules to medicine. Physiol Rev 2002; 82:205-244
4. Goel M, Sinkins WG, Zuo CD, et al: Vasopressin-induced membrane traffcking of TRPC3 and AQP2 channels in cells of the rat renal collecting duct. Am J Physiol Renal Physiol 2007; 293:F1476-F1488
5. Gong H, Wang W, Kwon TH, et al: EPO and alpha-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. Kidney Int 2004; 66:683-695
6. Bohn AB, Nørregaard R, Stødkilde L, et al: Treatment with the vascular disrupting agent combretastatin is associated with impaired AQP2 traffcking and increased urine output. Am J Physiol Regul Integr Comp Physiol 2012; 303:R186-R198
7. Kwon TH, Frøkiaer J, Han JS, et al: Decreased abundance of major Na(+) transporters in kidneys of rats with ischemia-induced acute renal failure. Am J Physiol Renal Physiol 2000; 278:F925-F939
8. Liu X, Zhang T, Xia W, et al: Recombinant human erythropoietin pretreatment alleviates renal glomerular injury induced by cardiopulmonary bypass by reducing transient receptor potential channel 6-nuclear factor of activated T-cells pathway activation. J Thorac Cardiovasc Surg 2013; 146:681-687
9. Yang CW, Li C, Jung JY, et al: Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 2003; 17:1754-1755
10. Vesey DA, Cheung C, Pat B, et al: Erythropoietin protects against isch-aemic acute renal injury. Nephrol Dial Transplant 2004; 19:348-355
11. Hsu YJ, Hoenderop JG, Bindels RJ: TRP channels in kidney disease. Biochim Biophys Acta 2007; 1772:928-936
12. Goel M, Sinkins WG, Zuo CD, et al: Identifcation and localization of TRPC channels in the rat kidney. Am J Physiol Renal Physiol 2006; 290:F1241-F1252
13. Reiser J, Polu KR, Möller CC, et al: TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 2005; 37:739-744
14. El Hindi S, Reiser J: TRPC channel modulation in podocytes-inching toward novel treatments for glomerular disease. Pediatr Nephrol 2011; 26:1057-1064
15. Wang Y, Jarad G, Tripathi P, et al: Activation of NFAT signaling in podocytes causes glomerulosclerosis. J Am Soc Nephrol 2010; 21:1657-1666
16. Schlöndorff J, Del Camino D, Carrasquillo R, et al: TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcription. Am J Physiol Cell Physiol 2009; 296:C558-C569
17. Chu X, Tong Q, Cheung JY, et al: Interaction of TRPC2 and TRPC6 in erythropoietin modulation of calcium infux. J Biol Chem 2004; 279:10514-10522
18. Tanaka T, Nangaku M: Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents. Exp Cell Res 2012; 318:1068-1073
19. Westenfelder C, Biddle DL, Baranowski RL: Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999; 55:808-820
20. Aydin Z, Duijs J, Bajema IM, et al. Erythropoietin, progenitors, and repair. Kidney Int Suppl 2007; 107:S16-12
21. Leist M, Ghezzi P, Grasso G, et al: Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004; 305:239-242
22. Brines M, Grasso G, Fiordaliso F, et al: Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit het-eroreceptor. Proc Natl Acad Sci USA 2004; 101:14907-14912
23. Ishii Y, Sawada T, Murakami T, et al: Renoprotective effect of erythropoietin against ischaemia-reperfusion injury in a non-human primate model. Nephrol Dial Transplant 2011; 26:1157-1162
24. Sharples EJ, Patel N, Brown P, et al: Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004; 15:2115-2124
25. Nakazawa Y, Nishino T, Obata Y, et al: Recombinant human erythropoietin attenuates renal tubulointerstitial injury in murine adriamycin-induced nephropathy. J Nephrol 2013; 26:527-533
26. Vesey DA, Cheung C, Pat B, et al: Erythropoietin protects against isch-aemic acute renal injury. Nephrol Dial Transplant 2004; 19:348-355
27. Vaziri ND, Zhou XJ, Liao SY: Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol 1994; 266:F360-F366
28. Topcu SO, Nørregaard R, Pedersen M, et al: Regulation of aquaporins and sodium transporter proteins in the solitary kidney in response to partial ureteral obstruction in neonatal rats. Urol Int 2011; 87:94-104
29. Lee S, Kim W, Moon SO, et al: Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant 2006; 21:2096-2105
30. Thai TL, Blount MA, Klein JD, et al: Lack of protein kinase C - a leads to impaired urine concentrating ability and decreased aquaporin-2 in angiotensin II-induced hypertension. Am J Physiol Renal Physiol 2012; 303:F37-F44
31. Goel M, Sinkins W, Keightley A, et al: Proteomic analysis of TRPC5-and TRPC6-binding partners reveals interaction with the plasmalem-mal Na(+)/K(+)-ATPase. Pfugers Arch 2005; 451:87-98
32. Mazzochi C, Benos DJ, Smith PR: Interaction of epithelial ion channels with the actin-based cytoskeleton. Am J Physiol Renal Physiol 2006; 291:F1113-F1122
33. Wagner MC, Blazer-Yost BL, Boyd-White J, et al: Expression of the unconventional myosin Myo1c alters sodium transport in M1 collecting duct cells. Am J Physiol Cell Physiol 2005; 289:C120-C129
34. Mohler PJ, Davis JQ, Bennett V: Ankyrin-B coordinates the Na/K ATPase, Na/Ca exchanger, and InsP3 receptor in a cardiac T-tubule/SR microdomain. PLoS Biol 2005; 3:e423
35. Song YR, Lee T, You SJ, et al: Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: A pilot study. Am J Nephrol 2009; 30:253-260
36. Endre ZH, Walker RJ, Pickering JW, et al: Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010; 77:1020-1030
37. Kim JH, Shim JK, Song JW, et al: Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: A double blind, randomized clinical trial of effcacy and safety. Crit Care 2013; 17:R254
38. Oh SW, Chin HJ, Chae DW, et al: Erythropoietin improves long-term outcomes in patients with acute kidney injury after coronary artery bypass grafting. J Korean Med Sci 2012; 27:506-511
39. Brines M, Cerami A: Erythropoietin-mediated tissue protection: Reducing collateral damage from the primary injury response. J Intern Med 2008; 264:405-432
40. Masuda S, Nagao M, Takahata K, et al: Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 1993; 268:11208-11216
41. Coleman TR, Westenfelder C, Tögel FE, et al: Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci USA 2006; 103:5965-5970